Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23638878 | 0.90 | DRD2 (0.43) | DRD2HTR2CSCN9AKDM1ARCOR1 | |
| SCHEMBL20063500 | 0.89 | SCN9A (0.47) | DRD2HTR2CSCN9AHTR2BHTR2A | |
| SCHEMBL23639055 | 0.85 | SCN9A (0.43) | DRD2HTR2CSCN9A | |
| SCHEMBL23140999 | 0.81 | DRD2 (0.51) | DRD2HTR2CSCN9AKDM1ARCOR1 | |
| SCHEMBL23140860 | 0.81 | DRD2 (0.51) | DRD2HTR2CSCN9AKDM1ARCOR1 | |
| SCHEMBL23638950 | 0.76 | SCN9A (0.48) | DRD2HTR2CSCN9AHTR2BCHRM2 | |
| SCHEMBL23639026 | 0.75 | SCN9A (0.47) | DRD2HTR2CSCN9AHTR2BCHRM2 | |
| SCHEMBL23638885 | 0.75 | SCN9A (0.42) | DRD2SCN9ATACR1HTR1ADRD3 | |
| SCHEMBL23638881 | 0.74 | SCN9A (0.35) | SCN9ATACR1 | |
| SCHEMBL23638947 | 0.73 | SCN9A (0.48) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214336-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2021-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214336-A1 | PYRIDINE-SULFONAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | SCN1B, CACNA1A, SCN1A | DRD2 1985/4885HTR2C 1563/4885SCN9A 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.